Patients Urge NHS to Approve New Alzheimer’s Drugs Amid Cost Concerns
Audio narration · Coming soon
Patients and charities are pressing the NHS and the health spending watchdog Nice to approve new Alzheimer’s therapies that may slow cognitive decline. This demand comes despite ongoing concerns about the drugs' cost and potential side effects. The situation highlights the tension between access to innovative treatments and healthcare budget constraints.
Why this matters
PRISM scored this story 60/100 for interest.
Originally published by gnews